US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

13.28

+0.95007.70%

Post-market: 13.280.00000.00%17:19 EDT

Volume:128.96K

Turnover:1.71M

Market Cap:495.82M

PE:-6.12

High:13.59

Open:12.46

Low:12.46

Close:12.33

52wk High:16.33

52wk Low:3.35

Shares:37.34M

Float Shares:22.09M

Volume Ratio:0.18

T/O Rate:0.58%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1700

EPS(LYR):-2.1700

ROE:-26.13%

ROA:-17.38%

PB:1.90

PE(LYR):-6.12

Loading ...

Overview Company News Filings

Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis

MT Newswires Live

Contineum Therapeutics Is Maintained at Outperform by RBC Capital

Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback

Contineum Therapeutics Inc : Jonestrading Cuts Target Price to $22 From $25

THOMSON REUTERS

Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from RBC Capital

Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF

RBC Lowers Price Target on Contineum Therapeutics to $22 From $25, Keeps Outperform, Speculative Risk

MT Newswires Live

Stocks to Watch: Contineum, Gap Inc., Geospace Technologies

Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments

Contineum Therapeutics MS Treatment Fails to Meet Trial Endpoints

BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Contineum Therapeutics Reports Phase 2 Trial Results

Contineum Phase 2 VISTA trial did not meet primary, secondary endpoints

Contineum Therapeutics Inc trading halted, news pending

Contineum Therapeutics Reports Phase 2 VISTA Trial of PIPE-307 Misses Efficacy Endpoints in RRMS

Contineum Therapeutics Inc - Pipe-307 Shows No Significant Change in Lcla

THOMSON REUTERS

Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (Rrms)

THOMSON REUTERS

Contineum Therapeutics Inc - Trial Did Not Meet Primary or Secondary Efficacy Endpoints

THOMSON REUTERS

Contineum Therapeutics Inc - Pipe-307 Shows Acceptable Safety and Tolerability

THOMSON REUTERS

NASDAQ TRADE HALT HALT NEWS PENDING AT 04:01 PM

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CTNM/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTNM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","market":"US","secType":"STK","nameCN":"Contineum Therapeutics, INC.","latestPrice":13.28,"timestamp":1774468800000,"preClose":12.33,"halted":0,"volume":128959,"hourTrading":{"tag":"盘后","latestPrice":13.28,"preClose":13.28,"latestTime":"17:19 EDT","volume":12743,"amount":169227.04,"timestamp":1774473580647,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.07704785077047845,"floatShares":22092600,"shares":37336000,"eps":-2.169999,"marketStatus":"Closed","change":0.95,"latestTime":"03-25 16:00:00 EDT","open":12.46,"high":13.59,"low":12.46,"amount":1709847.3923550001,"amplitude":0.091646,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.169999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774512000000},"marketStatusCode":5,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":12.33,"postHourTrading":{"tag":"盘后","latestPrice":13.28,"preClose":13.28,"latestTime":"17:19 EDT","volume":12743,"amount":169227.04,"timestamp":1774473580647,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.184449,"impliedVol":0.7729,"impliedVolPercentile":0.3112},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","floatShares":22092600,"roa":"-17.38%","roe":"-26.13%","lyrEps":-2.169999,"volumeRatio":0.184449,"shares":37336000,"dividePrice":0,"high":13.59,"amplitude":0.091646,"preClose":12.33,"low":12.46,"week52Low":3.35,"pbRate":"1.90","week52High":16.33,"institutionHeld":0,"latestPrice":13.28,"eps":-2.169999,"divideRate":0,"volume":128959,"delay":0,"ttmEps":-2.169999,"open":12.46,"prevYearClose":11.43,"prevWeekClose":12.21,"prevMonthClose":15.34,"prevQuarterClose":11.43,"fiveDayClose":12.22,"twentyDayClose":15.78,"sixtyDayClose":12.41},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTNM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-05","symbol":"CTNM","fiscalQuarterEnding":"2025/12","expectedEps":-0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-10-30","symbol":"CTNM","fiscalQuarterEnding":"2025/09","expectedEps":-0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1761796800000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2025-08-05","symbol":"CTNM","fiscalQuarterEnding":"2025/06","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2025-05-14","symbol":"CTNM","fiscalQuarterEnding":"2025/03","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.62}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTNM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTNM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.2857,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1767931200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTNM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTNM","date":"2026-03-24","current":-6.119818,"percent":0.318565,"low":-16.425726,"twenty":-9.997963,"median":-5.454317,"eighty":-2.044554,"high":28.322904,"avg":-2.908701,"sd":10.764937,"marketCap":463713567},"quantilePoints":[{"date":"2024-04-05","current":16.281367,"twenty":16.281367,"median":16.281367,"eighty":16.281367,"marketCap":369912656},{"date":"2024-04-12","current":17.609251,"twenty":16.281367,"median":16.569509,"eighty":16.868158,"marketCap":400082176},{"date":"2024-04-19","current":17.122563,"twenty":16.281367,"median":16.868158,"eighty":17.144685,"marketCap":389024629},{"date":"2024-04-26","current":17.686678,"twenty":16.315104,"median":17.089379,"eighty":17.59819,"marketCap":401841332},{"date":"2024-05-03","current":16.48102,"twenty":16.48102,"median":17.122563,"eighty":17.59819,"marketCap":374448771},{"date":"2024-05-10","current":17.719862,"twenty":16.38147,"median":17.105971,"eighty":17.59819,"marketCap":402595255},{"date":"2024-05-17","current":16.547386,"twenty":16.392531,"median":17.100441,"eighty":17.487579,"marketCap":375956618},{"date":"2024-05-24","current":17.819411,"twenty":16.48102,"median":17.133624,"eighty":17.59819,"marketCap":404857026},{"date":"2024-05-31","current":20.173009,"twenty":16.534113,"median":17.172337,"eighty":17.68889,"marketCap":385849140},{"date":"2024-06-07","current":21.67926,"twenty":16.768608,"median":17.354846,"eighty":18.209439,"marketCap":414659209},{"date":"2024-06-14","current":22.311348,"twenty":16.85046,"median":17.388029,"eighty":20.619504,"marketCap":426749148},{"date":"2024-06-21","current":26.466988,"twenty":16.894704,"median":17.487579,"eighty":21.17897,"marketCap":506234071},{"date":"2024-06-28","current":25.216261,"twenty":16.921251,"median":17.542884,"eighty":21.517876,"marketCap":482311425},{"date":"2024-07-05","current":27.018383,"twenty":16.987617,"median":17.609251,"eighty":21.78147,"marketCap":516780614},{"date":"2024-07-12","current":28.242212,"twenty":17.042923,"median":17.692208,"eighty":22.916538,"marketCap":540188796},{"date":"2024-07-15","current":27.932893,"twenty":17.049559,"median":17.697739,"eighty":23.766494,"marketCap":534272442},{"date":"2024-08-02","current":26.224911,"twenty":17.056196,"median":17.697739,"eighty":24.100021,"marketCap":501603882},{"date":"2024-08-09","current":22.338245,"twenty":17.08938,"median":17.819411,"eighty":24.409341,"marketCap":427263614},{"date":"2024-08-16","current":-15.206885,"twenty":17.023013,"median":17.769636,"eighty":24.100021,"marketCap":478195700},{"date":"2024-08-23","current":-14.92058,"twenty":16.547386,"median":17.697739,"eighty":23.683112,"marketCap":469192554},{"date":"2024-08-30","current":-15.468649,"twenty":16.315104,"median":17.614781,"eighty":23.293101,"marketCap":486427149},{"date":"2024-09-06","current":-14.511573,"twenty":15.417858,"median":17.570537,"eighty":22.830467,"marketCap":456330916},{"date":"2024-09-13","current":-14.765157,"twenty":-14.025672,"median":17.410151,"eighty":22.682531,"marketCap":464305131},{"date":"2024-09-20","current":-16.425726,"twenty":-14.408503,"median":17.365907,"eighty":22.459283,"marketCap":516523382},{"date":"2024-09-27","current":-15.272326,"twenty":-14.745525,"median":17.19999,"eighty":22.405488,"marketCap":480253562},{"date":"2024-10-04","current":-14.421591,"twenty":-14.887859,"median":17.133624,"eighty":22.351694,"marketCap":453501355},{"date":"2024-10-11","current":-13.521775,"twenty":-14.788061,"median":17.100441,"eighty":22.316727,"marketCap":425205752},{"date":"2024-10-18","current":-13.480875,"twenty":-14.745525,"median":17.039604,"eighty":22.010098,"marketCap":423919588},{"date":"2024-10-25","current":-13.309092,"twenty":-14.662087,"median":16.868158,"eighty":21.934785,"marketCap":418517700},{"date":"2024-10-31","current":-14.004404,"twenty":-14.595828,"median":16.547386,"eighty":21.78147,"marketCap":440382485},{"date":"2024-11-08","current":-13.455721,"twenty":-14.532841,"median":16.387,"eighty":21.655052,"marketCap":477166769},{"date":"2024-11-15","current":-13.193473,"twenty":-14.477216,"median":16.281367,"eighty":21.566291,"marketCap":467866942},{"date":"2024-11-22","current":-10.423934,"twenty":-14.434679,"median":15.167037,"eighty":21.517876,"marketCap":369653551},{"date":"2024-11-29","current":-10.838275,"twenty":-14.411775,"median":-9.795154,"eighty":21.388769,"marketCap":384346893},{"date":"2024-12-06","current":-10.358512,"twenty":-14.347406,"median":-10.271282,"eighty":21.17897,"marketCap":367333550},{"date":"2024-12-13","current":-10.031401,"twenty":-14.270231,"median":-10.358512,"eighty":21.154762,"marketCap":355733543},{"date":"2024-12-20","current":-9.70429,"twenty":-14.217087,"median":-10.242206,"eighty":20.950342,"marketCap":344133536},{"date":"2024-12-27","current":-10.569317,"twenty":-14.14183,"median":-10.271282,"eighty":20.635643,"marketCap":374809110},{"date":"2025-01-03","current":-10.525702,"twenty":-14.135286,"median":-10.358512,"eighty":20.603366,"marketCap":373262442},{"date":"2025-01-10","current":-9.718828,"twenty":-14.073857,"median":-10.358512,"eighty":20.25908,"marketCap":344649092},{"date":"2025-01-17","current":-9.071876,"twenty":-14.047944,"median":-10.256744,"eighty":19.850241,"marketCap":321706856},{"date":"2025-01-24","current":-8.19958,"twenty":-14.045305,"median":-10.209494,"eighty":18.599466,"marketCap":290773505},{"date":"2025-01-31","current":-7.429052,"twenty":-14.035488,"median":-10.009594,"eighty":17.759682,"marketCap":263449044},{"date":"2025-02-07","current":-6.883867,"twenty":-14.024036,"median":-9.925999,"eighty":17.706588,"marketCap":244115699},{"date":"2025-02-14","current":-5.589962,"twenty":-14.010948,"median":-9.718828,"eighty":17.697739,"marketCap":198231228},{"date":"2025-02-21","current":-5.742614,"twenty":-13.988044,"median":-9.667944,"eighty":17.693315,"marketCap":203644564},{"date":"2025-02-28","current":-5.19016,"twenty":-13.940599,"median":-9.518928,"eighty":17.660132,"marketCap":184053442},{"date":"2025-03-07","current":-3.942751,"twenty":-13.847345,"median":-9.071876,"eighty":17.615888,"marketCap":166612775},{"date":"2025-03-14","current":-4.371311,"twenty":-13.716463,"median":-8.19958,"eighty":17.604827,"marketCap":184722859},{"date":"2025-03-21","current":-4.377433,"twenty":-13.63957,"median":-8.126889,"eighty":17.576068,"marketCap":184981575},{"date":"2025-03-28","current":-4.561102,"twenty":-13.619937,"median":-7.567165,"eighty":17.520762,"marketCap":192743040},{"date":"2025-04-04","current":-3.75296,"twenty":-13.617995,"median":-7.116479,"eighty":17.456608,"marketCap":158592595},{"date":"2025-04-11","current":-2.528503,"twenty":-13.600664,"median":-6.847522,"eighty":17.401302,"marketCap":106849497},{"date":"2025-04-17","current":-2.681561,"twenty":-13.574128,"median":-6.436815,"eighty":17.385817,"marketCap":113317384},{"date":"2025-04-25","current":-2.767272,"twenty":-13.55286,"median":-5.742614,"eighty":17.372544,"marketCap":116939401},{"date":"2025-05-02","current":-2.430547,"twenty":-13.541408,"median":-5.640845,"eighty":17.334936,"marketCap":102710049},{"date":"2025-05-09","current":-2.418302,"twenty":-13.513595,"median":-5.553616,"eighty":17.244235,"marketCap":102192618},{"date":"2025-05-16","current":-2.045592,"twenty":-13.477603,"median":-5.430041,"eighty":17.188929,"marketCap":101933903},{"date":"2025-05-23","current":-2.030017,"twenty":-13.462755,"median":-5.321004,"eighty":17.144685,"marketCap":101157756},{"date":"2025-05-30","current":-1.853493,"twenty":-13.455721,"median":-5.117468,"eighty":17.144685,"marketCap":92361429},{"date":"2025-06-06","current":-2.154621,"twenty":-13.448154,"median":-4.770625,"eighty":17.122563,"marketCap":107366928},{"date":"2025-06-13","current":-2.40383,"twenty":-13.399073,"median":-4.628447,"eighty":17.122563,"marketCap":119785271},{"date":"2025-06-20","current":-1.895028,"twenty":-13.379975,"median":-4.585591,"eighty":17.104865,"marketCap":94431153},{"date":"2025-06-27","current":-2.081935,"twenty":-13.328858,"median":-4.536848,"eighty":17.091592,"marketCap":103744911},{"date":"2025-07-03","current":-2.014441,"twenty":-13.312364,"median":-4.445597,"eighty":17.06947,"marketCap":100381610},{"date":"2025-07-11","current":-2.092319,"twenty":-13.309092,"median":-4.377433,"eighty":17.036286,"marketCap":104262342},{"date":"2025-07-18","current":-1.993674,"twenty":-13.304184,"median":-4.325394,"eighty":16.96992,"marketCap":99346748},{"date":"2025-07-25","current":-2.959359,"twenty":-13.281279,"median":-4.150909,"eighty":16.894704,"marketCap":147467829},{"date":"2025-08-01","current":-3.063196,"twenty":-13.22336,"median":-4.01928,"eighty":16.841612,"marketCap":152642139},{"date":"2025-08-08","current":-3.062072,"twenty":-13.164683,"median":-3.75296,"eighty":16.657997,"marketCap":174115524},{"date":"2025-08-15","current":-3.58032,"twenty":-12.764301,"median":-3.489183,"eighty":16.507566,"marketCap":203584157},{"date":"2025-08-22","current":-4.951297,"twenty":-12.507357,"median":-3.639499,"eighty":16.427927,"marketCap":281540625},{"date":"2025-08-29","current":-4.956228,"twenty":-11.906412,"median":-3.948873,"eighty":16.385894,"marketCap":281821044},{"date":"2025-09-05","current":-5.419796,"twenty":-11.370375,"median":-4.039068,"eighty":16.354924,"marketCap":308180426},{"date":"2025-09-12","current":-5.824184,"twenty":-11.101417,"median":-4.150909,"eighty":16.301609,"marketCap":331174779},{"date":"2025-09-19","current":-6.115147,"twenty":-10.938589,"median":-4.325394,"eighty":16.232919,"marketCap":347719498},{"date":"2025-09-26","current":-5.355685,"twenty":-10.838275,"median":-4.374303,"eighty":15.930178,"marketCap":304534979},{"date":"2025-10-03","current":-5.301438,"twenty":-10.774307,"median":-4.411924,"eighty":15.250644,"marketCap":301450371},{"date":"2025-10-10","current":-5.996789,"twenty":-10.666723,"median":-4.53049,"eighty":8.143309,"marketCap":340989443},{"date":"2025-10-17","current":-6.144737,"twenty":-10.617293,"median":-4.573346,"eighty":-1.787038,"marketCap":349402011},{"date":"2025-10-24","current":-5.483906,"twenty":-10.566409,"median":-4.58636,"eighty":-1.820784,"marketCap":311825872},{"date":"2025-10-31","current":-5.197875,"twenty":-10.55914,"median":-4.692731,"eighty":-1.833764,"marketCap":295561573},{"date":"2025-11-07","current":-5.410266,"twenty":-10.548963,"median":-4.832939,"eighty":-1.851935,"marketCap":321299446},{"date":"2025-11-14","current":-5.356212,"twenty":-10.534425,"median":-4.919242,"eighty":-1.870107,"marketCap":318089369},{"date":"2025-11-21","current":-6.004854,"twenty":-10.522794,"median":-4.956228,"eighty":-1.897105,"marketCap":356610284},{"date":"2025-11-28","current":-5.439749,"twenty":-10.511164,"median":-5.1056,"eighty":-1.907489,"marketCap":323050396},{"date":"2025-12-05","current":-5.395524,"twenty":-10.480633,"median":-5.127036,"eighty":-1.940717,"marketCap":320423970},{"date":"2025-12-12","current":-6.422541,"twenty":-10.474818,"median":-5.15474,"eighty":-1.961484,"marketCap":381415418},{"date":"2025-12-19","current":-5.596996,"twenty":-10.473364,"median":-5.194017,"eighty":-1.980175,"marketCap":332388800},{"date":"2025-12-26","current":-6.230896,"twenty":-10.467549,"median":-5.225482,"eighty":-1.988482,"marketCap":370034239},{"date":"2026-01-02","current":-5.616652,"twenty":-10.432657,"median":-5.250562,"eighty":-1.988482,"marketCap":333556100},{"date":"2026-01-09","current":-5.640545,"twenty":-10.418119,"median":-5.238277,"eighty":-1.992636,"marketCap":334975047},{"date":"2026-01-16","current":-7.282885,"twenty":-10.370143,"median":-5.311221,"eighty":-1.993674,"marketCap":432508676},{"date":"2026-01-23","current":-7.76882,"twenty":-10.358512,"median":-5.340862,"eighty":-1.996789,"marketCap":461366940},{"date":"2026-01-30","current":-8.980584,"twenty":-10.345428,"median":-5.356212,"eighty":-2.000423,"marketCap":533329955},{"date":"2026-02-06","current":-8.906771,"twenty":-10.297451,"median":-5.376869,"eighty":-2.009249,"marketCap":528946421},{"date":"2026-02-13","current":-9.152815,"twenty":-10.253836,"median":-5.386426,"eighty":-2.014441,"marketCap":543558201},{"date":"2026-02-20","current":-9.841736,"twenty":-10.233483,"median":-5.400438,"eighty":-2.020671,"marketCap":584471184},{"date":"2026-02-27","current":-9.706412,"twenty":-10.211675,"median":-5.415031,"eighty":-2.032093,"marketCap":576434705},{"date":"2026-03-06","current":-8.494648,"twenty":-10.131715,"median":-5.429659,"eighty":-2.035208,"marketCap":504471690},{"date":"2026-03-13","current":-8.627788,"twenty":-10.022678,"median":-5.439635,"eighty":-2.037285,"marketCap":517477458},{"date":"2026-03-20","current":-7.538421,"twenty":-10.003778,"median":-5.449385,"eighty":-2.042477,"marketCap":452139395},{"date":"2026-03-24","current":-7.731394,"twenty":-9.997963,"median":-5.454317,"eighty":-2.044554,"marketCap":463713567}],"updateTime":1774480727650},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTNM\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2585276123","title":"Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2585276123","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585276123?lang=en_us&edition=fundamental","pubTime":"2025-11-22 04:18","pubTimestamp":1763756289,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics  shares were down about 10% in recent Friday trading after the company said late Thursday that its phase 2 trial of PIPE-307, in development for the treatment of patients with relapsing-remitting multiple sclerosis, failed to meet its primary and secondary efficacy goals.The company said PIPE-307 showed an acceptable safety and tolerability profile. Contineum said it is continuing to analyze exploratory endpoints and plans to present the full dataset at a future medical meeting.The company said it remains committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases.Price: 10.93, Change: -1.29, Percent Change: -10.56","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PIPE","CTNM","BK4007"],"gpt_icon":0},{"id":"2585490181","title":"Contineum Therapeutics Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2585490181","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585490181?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:45","pubTimestamp":1763736300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 09:45 ET (14:45 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM"],"gpt_icon":0},{"id":"2585143314","title":"Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2585143314","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585143314?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:55","pubTimestamp":1763729718,"startTime":"0","endTime":"0","summary":"Debanjana Chatterjee, an analyst from JonesTrading, reiterated the Buy rating on Contineum Therapeutics, Inc. Class A. The associated price target ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/contineum-therapeutics-undervalued-potential-in-ipf-with-pipe-791-amidst-pipe-307-setback-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/contineum-therapeutics-undervalued-potential-in-ipf-with-pipe-791-amidst-pipe-307-setback-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","PIPE","BK4007"],"gpt_icon":0},{"id":"2585102371","title":"Contineum Therapeutics Inc : Jonestrading Cuts Target Price to $22 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2585102371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585102371?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:18","pubTimestamp":1763727494,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WX0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585635110","title":"Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2585635110","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585635110?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:56","pubTimestamp":1763726193,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Contineum Therapeutics, Inc. Class A, with a price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/contineum-therapeutics-inc-class-a-ctnm-gets-a-buy-from-rbc-capital-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/contineum-therapeutics-inc-class-a-ctnm-gets-a-buy-from-rbc-capital-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029864427.USD","LU0128525929.USD","CTNM","LU1267930573.SGD","LU0708994859.HKD","LU0310800379.SGD","BK4207","BK4007"],"gpt_icon":0},{"id":"2585848110","title":"Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2585848110","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585848110?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:55","pubTimestamp":1763726151,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on CTNM stock, giving a Buy rating yesterday. Paul Matteis has given his B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-contineum-therapeutics-despite-setbacks-driven-by-pipe-791s-potential-in-ipf-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-contineum-therapeutics-despite-setbacks-driven-by-pipe-791s-potential-in-ipf-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","BK4007","PIPE"],"gpt_icon":0},{"id":"2585117561","title":"RBC Lowers Price Target on Contineum Therapeutics to $22 From $25, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2585117561","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585117561?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:32","pubTimestamp":1763724747,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics (CTNM) has an average rating of buy and mean price target of $22.83, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CTNM"],"gpt_icon":0},{"id":"2585166553","title":"Stocks to Watch: Contineum, Gap Inc., Geospace Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2585166553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585166553?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:31","pubTimestamp":1763681460,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics said its drug designed to treat multiple sclerosis didn't meet its trial endpoints. The stock fell 12%, to $10.75, in after-hours trading Thursday.Gap Inc. raised its fiscal-year sales outlook after its three main brands logged same-store sales growth. Shares advanced 4.8%, to $24.16, after the bell.Geospace Technologies said oil volatility and less offshore exploration resulted in an 11% drop in quarterly sales. The stock declined 11%, to $15.35.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GAP","BK4094","BK4007","GEOS","BK4179","CTNM","BK4585"],"gpt_icon":0},{"id":"2585657811","title":"Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2585657811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585657811?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:05","pubTimestamp":1763679930,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on CTNM stock, giving a Buy rating on November 6. Myles Minter has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-contineum-therapeutics-amid-promising-pipe-791-developments-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-contineum-therapeutics-amid-promising-pipe-791-developments-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","PIPE"],"gpt_icon":0},{"id":"2585168067","title":"Contineum Therapeutics MS Treatment Fails to Meet Trial Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168067","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168067?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:07","pubTimestamp":1763676420,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics said a trial of its treatment for relapsing-remitting multiple sclerosis didn't meet its primary or secondary efficacy endpoints.The San Diego biopharmaceutical company said Thursday that topline data from a phase 2 trial of PIPE-307 showed no significant change in patients' binocular 2.5% low contrast letter acuity.The company plans to interrogate the trial data related to its exploratory endpoints.\"We intend to learn from these data and remain committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases,\" Chief Medical Officer Timothy Watkins said.Shares slid 15%, to $10.33, in after-hours trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Contineum Therapeutics MS Treatment Fails to Meet Trial Endpoints","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550577.SGD","LU0158827781.USD","LU1162221912.USD","LU0912757837.SGD","LU1548497426.USD","LU1668664300.SGD","LU1791710400.SGD","LU1244550494.USD","BK4581","LU0320765646.SGD","LU0106261372.USD","BK4007","IE00BZ1G4Q59.USD","LU1732800096.USD","LU0528227936.USD","LU1732799900.SGD","LU2271345857.HKD","LU2133065610.SGD","LU1720051108.HKD","LU0006306889.USD","LU0106831901.USD","LU2023251221.USD","BK4588","LU1791710582.SGD","LU2357305700.SGD","LU0882574139.USD","LU0158827948.USD","LU1074936037.SGD","LU2111349929.HKD","LU0314104364.USD","LU2028103732.USD","LU1244550221.USD","IE00BKVL7J92.USD","CTNM","LU0557290698.USD","LU0971096721.USD","BK4504","LU2347655156.SGD","LU0267386448.USD","BK4516","LU0225283273.USD","LU0795875169.SGD","LU0795875086.SGD","LU1363072403.SGD","LU1720051017.SGD","LU1989772840.SGD","LU2089283258.USD","LU1989772923.USD","LU0234570918.USD","LU0098860793.USD"],"gpt_icon":0},{"id":"2585168593","title":"BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168593","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168593?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:43","pubTimestamp":1763674984,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis Nov 20 (Reuters) - Contineum Therapeutics Inc CTNM.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA6PCSB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585814168","title":"Contineum Therapeutics Reports Phase 2 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2585814168","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585814168?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:31","pubTimestamp":1763674290,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has shared an update. On November 20, 2025, Contineum Therapeutics reported topline data from its ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-reports-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-reports-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585715061","title":"Contineum Phase 2 VISTA trial did not meet primary, secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2585715061","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585715061?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:10","pubTimestamp":1763673035,"startTime":"0","endTime":"0","summary":"Contineum (CTNM) Therapeutics reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the tre...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/contineum-phase-2-vista-trial-did-not-meet-primary-secondary-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/contineum-phase-2-vista-trial-did-not-meet-primary-secondary-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4017","CTNM","VGZ","BK4007"],"gpt_icon":0},{"id":"2585815057","title":"Contineum Therapeutics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2585815057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585815057?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:06","pubTimestamp":1763672779,"startTime":"0","endTime":"0","summary":"16:01 EST Contineum (CTNM) Therapeutics Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/contineum-therapeutics-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/contineum-therapeutics-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2585157729","title":"Contineum Therapeutics Reports Phase 2 VISTA Trial of PIPE-307 Misses Efficacy Endpoints in RRMS","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157729","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157729?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:06","pubTimestamp":1763672768,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics Inc. announced topline results from its Phase 2 VISTA trial evaluating PIPE-307, an M1 receptor antagonist, for the treatment of relapsing-remitting multiple sclerosis . The study demonstrated that PIPE-307 had an acceptable safety and tolerability profile at both tested doses. However, the trial did not meet its prespecified primary or secondary efficacy endpoints, with no significant change observed in binocular 2.5% low contrast letter acuity across treatment arms. The company stated that it continues to analyze exploratory endpoints and plans to present the complete dataset at a future medical meeting, with full results to be published in a peer-reviewed medical journal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL2Kpb9Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585577881","title":"Contineum Therapeutics Inc - Pipe-307 Shows No Significant Change in Lcla","url":"https://stock-news.laohu8.com/highlight/detail?id=2585577881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585577881?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:05","pubTimestamp":1763672700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA6PCSB0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585157267","title":"Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (Rrms)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157267?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:05","pubTimestamp":1763672700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA6PCSB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2585157207","title":"Contineum Therapeutics Inc - Trial Did Not Meet Primary or Secondary Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157207?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:05","pubTimestamp":1763672700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA6PCSB0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585157200","title":"Contineum Therapeutics Inc - Pipe-307 Shows Acceptable Safety and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157200?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:05","pubTimestamp":1763672700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA6PCSB0:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585215749","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:01 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2585215749","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585215749?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:01","pubTimestamp":1763672510,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:01 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nAQN2L9MT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":76,"code":"91000000","status":"200"}]}}